135 related articles for article (PubMed ID: 23551110)
1. Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts.
Abbas N; Heyerdahl H; Bruland ØS; Brevik EM; Dahle J
Curr Radiopharm; 2013 Jun; 6(2):78-86. PubMed ID: 23551110
[TBL] [Abstract][Full Text] [Related]
2. Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice.
Heyerdahl H; Abbas N; Sponheim K; Mollatt C; Bruland Ø; Dahle J
Curr Radiopharm; 2013 Jun; 6(2):106-16. PubMed ID: 23551111
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
Abbas N; Bruland ØS; Brevik EM; Dahle J
Nucl Med Commun; 2012 Aug; 33(8):838-47. PubMed ID: 22643311
[TBL] [Abstract][Full Text] [Related]
4. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.
Heyerdahl H; Abbas N; Brevik EM; Mollatt C; Dahle J
PLoS One; 2012; 7(8):e42345. PubMed ID: 22879947
[TBL] [Abstract][Full Text] [Related]
5. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
6. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
Dahle J; Bruland OS; Larsen RH
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):186-92. PubMed ID: 18722269
[TBL] [Abstract][Full Text] [Related]
7. Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.
Abbas N; Heyerdahl H; Bruland OS; Borrebæk J; Nesland J; Dahle J
EJNMMI Res; 2011 Aug; 1(1):18. PubMed ID: 22214432
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
Chan C; Fonge H; Lam K; Reilly RM
Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
Costantini DL; McLarty K; Lee H; Done SJ; Vallis KA; Reilly RM
J Nucl Med; 2010 Jul; 51(7):1084-91. PubMed ID: 20554744
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
[TBL] [Abstract][Full Text] [Related]
11. Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting ²²⁷Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts.
Heyerdahl H; Røe K; Brevik EM; Dahle J
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):153-9. PubMed ID: 23790511
[TBL] [Abstract][Full Text] [Related]
12. Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab.
Heyerdahl H; Krogh C; Borrebæk J; Larsen Å; Dahle J
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):563-70. PubMed ID: 21195878
[TBL] [Abstract][Full Text] [Related]
13. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of [
Pougoue Ketchemen J; Njotu FN; Babeker H; Ahenkorah S; Tikum AF; Nwangele E; Henning N; Cleeren F; Fonge H
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2070-2084. PubMed ID: 38376808
[TBL] [Abstract][Full Text] [Related]
15. Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.
Repetto-Llamazares AH; Larsen RH; Patzke S; Fleten KG; Didierlaurent D; Pichard A; Pouget JP; Dahle J
PLoS One; 2015; 10(6):e0128816. PubMed ID: 26066655
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer.
Yoshida T; Jin K; Song H; Park S; Huso DL; Zhang Z; Liangfeng H; Zhu C; Bruchertseifer F; Morgenstern A; Sgouros G; Sukumar S
Oncotarget; 2016 May; 7(22):33306-15. PubMed ID: 27119227
[TBL] [Abstract][Full Text] [Related]
17. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
[TBL] [Abstract][Full Text] [Related]
18.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
19. Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Maecke HR; Forssell-Aronsson E
J Nucl Med; 2004 Sep; 45(9):1542-8. PubMed ID: 15347722
[TBL] [Abstract][Full Text] [Related]
20. Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.
Dahle J; Borrebaek J; Melhus KB; Bruland OS; Salberg G; Olsen DR; Larsen RH
Nucl Med Biol; 2006 Feb; 33(2):271-9. PubMed ID: 16546683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
